News from palatin technologies, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 16, 2022, 07:30 ET Palatin Reports Positive Interim Analysis in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Jul 26, 2022, 07:30 ET Palatin Announces Preliminary Fourth Quarter Vyleesi® Net Product Revenue Increased 225% Over Prior Quarter

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

May 17, 2022, 07:30 ET Palatin Reports Third Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Patient Enrollment on Track in Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease with Topline Results Currently Expected Second Half...

May 12, 2022, 08:00 ET Palatin Announces $15 Million Private Placement of Convertible Redeemable Preferred Stock

Palatin Technologies, Inc. ("Palatin" or the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based...

May 11, 2022, 09:02 ET Palatin to Report Third Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on May 17, 2022

Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter, fiscal year 2022 operating results on Tuesday, May 17, 2022, before...

May 02, 2022, 13:02 ET Palatin to Present at the Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Conference

Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Apr 21, 2022, 07:30 ET Palatin to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022

Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Mar 03, 2022, 07:30 ET Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Feb 15, 2022, 07:30 ET Palatin Reports Second Quarter Fiscal Year 2022 Financial Results and Provides Corporate Update

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Feb 10, 2022, 07:30 ET Palatin to Report Second Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on February 15, 2022

Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter, fiscal year 2022 operating results on Tuesday, February 15, 2022,...

Jan 21, 2022, 07:30 ET Palatin Announces Presentation at the 2022 Crohn's and Colitis Congress

Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Jan 07, 2022, 10:59 ET Palatin to Present at H.C. Wainwright BioConnect Conference

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Dec 28, 2021, 07:30 ET Palatin Announces Initiation of Pivotal Phase 3 PL9643 MELODY-1 Clinical Trial in Patients with Dry Eye Disease

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Nov 30, 2021, 07:30 ET Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Nov 15, 2021, 07:30 ET Palatin Reports First Quarter Fiscal Year 2022 Results and Provides Corporate Update

Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate...

Nov 10, 2021, 16:30 ET Palatin to Report First Quarter, Fiscal Year 2022 Results; Teleconference and Webcast to be held on November 15, 2021

Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter, fiscal year 2022 operating results on Monday, November 15, 2021,...

Oct 22, 2021, 07:30 ET Palatin Awarded "Top 10 Poster" Designation at the American Society of Retina Specialists (ASRS) 2021 Annual Meeting

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Sep 29, 2021, 07:30 ET Palatin Reports Fourth Quarter and Full Year Fiscal Year 2021 Financial Results and Provides Corporate Update

Palatin Technologies, Inc., (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate...

Sep 27, 2021, 07:30 ET Palatin Announces Presentation of Positive Protective Effects of PL8331 and PL9654 on Retinal Inflammation at the 2021 American Society of Retina Specialists (ASRS) Annual Meeting

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Sep 24, 2021, 07:30 ET Palatin To Report Fourth Quarter And Fiscal Year End 2021 Results; Teleconference And Webcast To Be Held On September 29, 2021

Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2021 operating results on Wednesday, September...

Sep 15, 2021, 07:30 ET Palatin to Present Peptides Platform at the TIDES USA Conference

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Sep 13, 2021, 07:00 ET Palatin to Participate in H.C. Wainwright 23rd Annual Global Investment Virtual Conference

Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that...

Jul 22, 2021, 17:28 ET Palatin Announces Presentation at the [email protected] Conference

Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that...

Jul 08, 2021, 16:15 ET Palatin Announces Adjournment of Annual Meeting of Stockholders

Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) announced that its 2021 Annual Meeting of Stockholders that convened on June 8, 2021 and...

Jun 29, 2021, 07:30 ET Palatin Announces Positive End-of-Phase 2 Meeting with FDA on PL9643 for the Treatment of Dry Eye Disease

Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN) a biopharmaceutical company developing first-in-class medicines based on molecules that...